T&L Co

T&L Co Receivables

The Accounts Receivable of T&L Co (340570.KQ) as of Oct 30, 2026 is 16.81 B KRW. In the previous year, Accounts Receivable was 10.40 B KRW — a change of 61.74% (higher).

Receivables

16.81 BKRW

YoY

61.74%

Last updated:

Accounts Receivable of T&L Co is 2024 16.81 B KRW. Accounts Receivable of T&L Co was 2023 10.40 B KRW. It decreases by 61.74% higher compared to the previous year.

The T&L Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
4.72 B KRW
Jan 1, 2018
4.57 B KRW
Jan 1, 2019
5.96 B KRW
Jan 1, 2020
7.09 B KRW
Jan 1, 2021
8.12 B KRW
Jan 1, 2022
13.38 B KRW
Jan 1, 2023
10.40 B KRW
Jan 1, 2024
16.81 B KRW
The T&L Co Receivables history
YEARReceivablesYoY
16.81 BKRW+61.74%
10.40 BKRW-22.31%
13.38 BKRW+64.72%
8.12 BKRW+14.60%
7.09 BKRW+18.90%
5.96 BKRW+30.49%
4.57 BKRW-3.18%
4.72 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

T&L Co Stock analysis

What does T&L Co do? T&L Co., Ltd. generates revenue through the sale of medical polymer material products including wound treatment materials like hydrocolloids, foams, and hydrogels, which are essential for wound healing. The company also offers orthopedic fixing materials such as casts and splints for fracture treatment, alongside structural adhesives and water repellents. Domestic and international markets, particularly the United States, Germany, China, and Dubai, purchase these products. The firm's product portfolio targets healthcare providers and medical facilities requiring specialized materials for patient care. T&L Co., Ltd. focuses on developing medical polymer materials that serve specific clinical needs, with wound treatment materials being a key segment. Orthopedic fixing materials are sold to hospitals and clinics for fracture management, while structural adhesives and water repellents cater to industrial applications. The company's international presence in the United States, Germany, China, and Dubai supports its market diversification strategy. The firm's revenue streams are derived from the consistent demand for medical polymer products in wound care, orthopedic solutions, and industrial adhesives. Products such as hydrocolloids, foams, and hydrogels are sold to healthcare providers, while orthopedic devices like casts and splints are distributed to medical institutions. Structural adhesives and water repellents are marketed to industrial clients in key global markets. T&L Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about T&L Co stock

Accounts Receivable of T&L Co is 16.81 B KRW in 2024.

Accounts Receivable of T&L Co changed from 10.40 B KRW to 16.81 B KRW, representing a 61.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable T&L Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's T&L Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — T&L Co

All Key Metrics — T&L Co